×
Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Biobanking Market Share

ID: MRFR/HC/4511-HCR
200 Pages
Rahul Gotadki
October 2025

Biobanking Market Research Report: Size, Share, Trend Analysis By Sample Type (Blood Products, Tissues, Cells, Nucleic Acids, Microbiome Samples), By Applications (Research and Development, Clinical Trials, Personalized Medicine, Regenerative Medicine), By End-use (Academic Research Institutions, Biotechnology Companies, Pharmaceutical Companies, Government Organizations), By Storage Type (Vapor Phase Storage, Liquid Phase Storage, Cryopreservation Storage), and By Regional (North America, Europe, South America, Asia Pacific, Middle East and... read more

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Biobanking Market Infographic
×
Biobanking Market Infographic Full View
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Market Share

Biobanking Market Share Analysis

The Biobanking market assumes an essential part in the field of clinical examination by putting away and overseeing usual samples for different purposes, including clinical studies and customized medicine. As the interest for excellent natural examples develops, organizations in the biobanking area decisively position themselves to catch a critical market share. Effective biobanking organizations center around differentiating the kinds of natural samples they store. This incorporates blood, tissues, cells, and DNA samples, taking special care of the various requirements of analysts across various logical disciplines. Offering a wide scope of test types upgrades an organization's enticement for a more extensive client base. Vigorous information management frameworks and severe safety efforts are fundamental in the biobanking business. Organizations put resources into cutting edge data innovation to guarantee exact example following, effective information recovery, and consistence with security guidelines. Focusing on information security upgrades client trust and supports an organization's market position. Perceiving the interesting prerequisites of examination substances, biobanking organizations offer altered administrations. Fitting answers for scholarly examination, drug advancement, or clinical preliminaries guarantees that clients get administrations lined up with their requirements, encouraging long haul associations and reliability. Driving biobanking organizations effectively take part in instructive drives. Studios, preparing projects, and workshops assist specialists and medical services experts with figuring out the significance of legitimate example assortment, stockpiling, and utilization. Instructing the market adds to a positive industry picture and advances the reception of biobanking administrations. Progressively, biobanking organizations highlight natural maintainability rehearses. This includes embracing eco-accommodating cycles, diminishing waste, and carrying out energy-effective measures in specimen storerooms. Green drives line up with worldwide supportability objectives as well as resound emphatically with earth cognizant clients. Forceful marketing procedures add to compelling market situating. Organizations use computerized stages, industry meetings, and logical distributions to advance their skill, highlight office capacities, and lay out areas of strength for a presence. Compelling marketing improves perceivability and draws in potential clients looking for dependable biobanking administrations.

Author
Rahul Gotadki
Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

Leave a Comment

FAQs

What is the projected growth of the Biobanking market?

The Biobanking market is the expected increase in total market value of 117.55 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion.

What is the size of the Biobanking market?

Biobanking market size was valued at approximately 75.39 billion USD in 2024. This figure will reach 117.55 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035.

What is the CAGR of the Biobanking market?

Biobanking market is expected to grow at a CAGR of 4.12% between 2025 and 2035.

How much will the Biobanking market be worth by 2035?

Biobanking market is expected to be worth of 117.55 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035.

How will the Biobanking market perform over the next 10 years?

Over the next 10 years the Biobanking market is expected to shift from usd billion 75.39 to 117.55 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035.

What was the market size of the Biobanking Market in 2024?

The Biobanking Market was valued at 5.14 billion USD in 2024.

What will the market size be for the European region in 2035?

The market size for Europe is projected to reach 2.1 billion USD by 2035.

What was the market size for blood products in 2024?

The market size for blood products in 2024 was 1.5 billion USD.

Who are the key players in the Biobanking Market?

Key players include Becton Dickinson, Biolife Solutions, and Thermo Fisher Scientific among others.

What is the anticipated market size for microbiome samples by 2035?

The anticipated market size for microbiome samples in 2035 is expected to be 0.2 billion USD.

Market Summary

As per MRFR analysis, the Biobanking Market Size was estimated at 75.39 USD Billion in 2024. The Biobanking industry is projected to grow from 78.5 USD Billion in 2025 to 117.55 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 4.12 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Biobanking Market is poised for substantial growth driven by technological advancements and increasing demand for personalized medicine.

  • Technological advancements are enhancing biobanking processes, leading to improved sample preservation and data management. North America remains the largest market for biobanking, while the Asia-Pacific region is emerging as the fastest-growing area. The research segment dominates the market, whereas the clinical trials segment is experiencing rapid growth due to rising demand for innovative therapies. Key market drivers include the rising demand for precision medicine and advancements in biobanking technologies, which are shaping the industry's future.

Market Size & Forecast

2024 Market Size 75.39 (USD Billion)
2035 Market Size 117.55 (USD Billion)
CAGR (2025 - 2035) 4.12%
Largest Regional Market Share in 2024 North America

Major Players

<p>Thermo Fisher Scientific (US), Qiagen (DE), Illumina (US), Merck KGaA (DE), STEMCELL Technologies (CA), BioLife Sciences (US), Tecan Group (CH), Biosample Solutions (US), ReproCELL (JP)</p>

Market Trends

The Biobanking Market is currently experiencing a transformative phase, characterized by advancements in technology and an increasing emphasis on personalized medicine. The integration of artificial intelligence and machine learning into biobanking processes appears to enhance data analysis and sample management, thereby improving research outcomes. 

Furthermore, the growing awareness of the importance of biobanks in drug development and disease prevention is likely to drive investment and collaboration among various stakeholders, including academic institutions, pharmaceutical companies, and healthcare organizations. This collaborative environment fosters innovation and accelerates the translation of research findings into clinical applications, which may ultimately benefit patient care. 

In addition, regulatory frameworks surrounding biobanking are evolving, suggesting a more structured approach to ethical considerations and data privacy. As biobanks expand their operations globally, adherence to these regulations becomes paramount. The Biobanking Market seems poised for growth, with an increasing number of biobanks emerging to meet the rising demand for biological samples. This trend indicates a robust future for biobanking, as it plays a crucial role in advancing scientific research and improving health outcomes across diverse populations.

Technological Advancements

The Biobanking Market is witnessing rapid technological innovations that enhance sample processing and data management. Automation and artificial intelligence are streamlining operations, improving accuracy, and reducing human error. These advancements may lead to more efficient biobanking practices, ultimately benefiting research and clinical applications.

Personalized Medicine Focus

There is a growing trend towards personalized medicine within the Biobanking Market. This approach emphasizes the need for tailored treatments based on individual genetic profiles. As a result, biobanks are increasingly collecting diverse biological samples to support the development of customized therapies, which could revolutionize patient care.

Regulatory Developments

The evolving regulatory landscape is shaping the Biobanking Market significantly. Stricter guidelines regarding ethical practices and data protection are emerging, which may influence how biobanks operate. Organizations are likely to adapt their strategies to ensure compliance, fostering trust and collaboration among stakeholders.

Biobanking Market Market Drivers

Market Growth Projections

The Global Biobanking Market Industry is projected to experience substantial growth, with estimates indicating a market value of 5.14 USD Billion in 2024 and a potential increase to 8 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate of 4.1% from 2025 to 2035. Factors contributing to this expansion include increasing demand for personalized medicine, advancements in technology, and growing investment in research and development. As the market evolves, it is likely to attract further interest from stakeholders across various sectors, including healthcare, pharmaceuticals, and biotechnology.

Regulatory Support and Standardization

Regulatory support and standardization are pivotal in shaping the Global Biobanking Market Industry. Governments are establishing frameworks to ensure ethical practices in biobanking, which enhances public trust and encourages participation. Standardization of sample collection, processing, and storage protocols is essential for maintaining data integrity and reproducibility in research. As regulatory bodies continue to refine guidelines, biobanks are better positioned to meet the demands of researchers and healthcare providers. This regulatory environment is likely to contribute to the market's growth, with projections indicating a rise to 5.14 USD Billion in 2024.

Rising Awareness of Biobanking Benefits

Rising awareness of the benefits of biobanking is driving participation and investment in the Global Biobanking Market Industry. Educational initiatives aimed at healthcare professionals and the public are highlighting the critical role biobanks play in advancing medical research and improving patient care. Increased understanding of how biobanks contribute to disease prevention, diagnosis, and treatment is likely to enhance public willingness to donate biological samples. This heightened awareness is expected to support the market's growth, with projections indicating a rise to 5.14 USD Billion in 2024 and further growth towards 8 USD Billion by 2035.

Technological Advancements in Biobanking

Technological advancements are transforming the Global Biobanking Market Industry, enabling more efficient sample management and data analysis. Innovations such as automated sample processing, advanced biorepositories, and sophisticated data analytics tools are enhancing the operational capabilities of biobanks. These technologies facilitate the integration of large datasets, allowing for more comprehensive research outcomes. As a result, biobanks can better support personalized medicine initiatives and large-scale epidemiological studies. The market's growth trajectory, with an expected value of 8 USD Billion by 2035, is indicative of the significant impact that technology has on biobanking practices.

Increasing Demand for Personalized Medicine

The Global Biobanking Market Industry is witnessing a surge in demand for personalized medicine, which relies heavily on biobanks for genetic and biological samples. This trend is driven by advancements in genomics and biotechnology, enabling tailored treatments for various diseases. For instance, biobanks facilitate the identification of genetic markers associated with specific conditions, thereby enhancing the efficacy of therapies. As the market evolves, the value is projected to reach 5.14 USD Billion in 2024, with expectations of expanding to 8 USD Billion by 2035, reflecting a compound annual growth rate of 4.1% from 2025 to 2035.

Growing Investment in Research and Development

Investment in research and development within the Global Biobanking Market Industry is on the rise, as governments and private entities recognize the importance of biobanks in advancing medical research. Funding initiatives are increasingly directed towards biobanking infrastructure, which supports the collection, storage, and analysis of biological samples. This investment not only enhances the capabilities of biobanks but also fosters collaboration between academic institutions and industry stakeholders. The anticipated growth in the market, reaching 8 USD Billion by 2035, underscores the critical role that R&D plays in driving innovation and improving healthcare outcomes.

Market Segment Insights

By Application: Research (Largest) vs. Clinical Trials (Fastest-Growing)

<p>In the Biobanking Market, the application segment is primarily dominated by Research, which accounts for a significant portion of the overall market share. Clinical Trials follow closely, benefiting from an ever-increasing focus on drug development and personalized medicine approaches. Regenerative Medicine and Pharmaceutical Development also contribute valuable segments but represent smaller proportions of the total application landscape. Together, these segments highlight an increasingly diversified approach within biobanking services to cater to various research needs and healthcare advancements.</p>

<p>Research (Dominant) vs. Regenerative Medicine (Emerging)</p>

<p>Research remains the dominant application within the biobanking sector, serving as a critical backbone for academic and clinical studies alike. It involves the collection, processing, and storage of biological samples that are essential for advancing scientific knowledge and medical innovations. In contrast, Regenerative Medicine is emerging rapidly, driven by advancements in stem cell research and tissue engineering, which aim to restore or replace damaged tissues and organs. Although still developing, Regenerative Medicine is capturing attention and investment, signaling its potential to reshape treatment paradigms in the future.</p>

By Sample Type: Blood (Largest) vs. Cells (Fastest-Growing)

<p>In the Biobanking Market, blood samples hold the largest market share, driven by their critical role in various medical and research applications such as diagnostics, therapeutic monitoring, and disease prevention. Tissue samples, while currently smaller in market share, are emerging as a significant contributor due to advancements in regenerative medicine and personalized therapies. </p> <p>The demand for diverse biological materials to support research is leading to an increase in tissue-banking initiatives, widening their application scope. The growth trends within the sample type segment are influenced by technological advancements and an increase in research activities. Blood samples are well-established and continue to dominate due to their ease of collection and extensive applications. </p> <p>However, tissue samples are gaining traction rapidlyrapid traction as innovations in sample preservation and analysis techniques enhance their utilization. The rising number of clinical trials and research studies focusing on tissue-based therapies significantly contributes to the robust growth of this segment.</p>

<p>Blood (Dominant) vs. Cells (Emerging)</p>

<p>Blood samples remain the dominant player in the Biobanking Market due to their reliability and extensive utility in medical research, diagnostics, and therapeutic applications. They are easier to collect and process, making them favorable among biobanks and research institutions. On the other hand, cells are emerging as a significant segment, driven by advancements in cell therapy and regenerative medicine. The growing focus on personalized medicine and innovations in cellular technologies is enhancing the prospects for cell samples, which are increasingly being integrated into biorepositories for future research and clinical applications.</p>

By Storage Type: Cryopreservation (Largest) vs. Liquid Nitrogen Storage (Fastest-Growing)

<p>In the Biobanking Market, the storage type segment exhibits diverse preferences, with Cryopreservation holding the largest market share. This method is widely adopted for preserving biological samples, particularly cells and tissues, due to its effectiveness in maintaining viability over extended periods. Additionally, Liquid Nitrogen Storage is gaining traction rapidly, indicating a growing preference for this advanced method among biobanks, especially for sensitive biological materials that require ultra-low temperatures for optimal preservation. Such demand is shaped by innovations in biorepositories and a surge in research activities. The growth trends within the storage type segment are largely fueled by advancements in storage technologies and increasing awareness of the importance of sample integrity. Cryopreservation continues to dominate as it is trusted for its reliability, while Liquid Nitrogen Storage is emerging as a popular choice because it allows for faster processing and handling of samples in laboratories. The increasing research investments in biotech and pharmaceuticals further drive the adoption of these storage techniques, aligning with the growing needs for efficient specimen handling in regenerative medicine and personalized therapies.</p>

<p>Cryopreservation (Dominant) vs. Liquid Nitrogen Storage (Emerging)</p>

<p>Cryopreservation is regarded as the dominant storage method in the Biobanking Market, providing a reliable solution for maintaining the integrity of biological specimens. Utilizing controlled freezing techniques, biobanks ensure long-term preservation of complex samples such as stem cells and various tissues, thus, facilitating extensive research and clinical applications. On the other hand, Liquid Nitrogen Storage represents the emerging trend, characterized by its ability to operate at extremely low temperatures essential for preserving fragile biological entities without damage. This method is increasingly preferred due to its efficiency and adaptability to modern laboratory needs, resulting in enhanced operational capabilities in handling various samples. As biobanks continue to evolve, both Cryopreservation and Liquid Nitrogen Storage are crucial in supporting innovative research, with the latter quickly becoming a viable alternative for future applications.</p>

By End User: Academic Institutions (Largest) vs. Pharmaceutical Companies (Fastest-Growing)

<p>In the biobanking market, academic institutions represent the largest segment, encompassing universities and research organizations that play a critical role in biobanking activities. Their significant share is attributed to their extensive research initiatives that demand reliable biological sample storage. Pharmaceutical companies are also substantial players in this segment, with increasing investments aimed at drug development and personalized medicine, thus expanding their biobanking operations significantly. As a result, while academic institutions retain a large presence, pharmaceutical companies are rapidly gaining ground in this market.</p>

<p>End User: Academic Institutions (Dominant) vs. Pharmaceutical Companies (Emerging)</p>

<p>Academic institutions are dominant in the biobanking market due to their reliance on biobanks for research and advancement in biomedical sciences. They typically manage large volumes of diverse biological samples that serve various studies, from genetics to disease pathology. In contrast, pharmaceutical companies are emerging forces leveraging advanced biobanking technologies to enhance their research capabilities. These companies seek to utilize biobanks to identify new drug targets and validate therapeutic biomarkers, positioning themselves powerfully to adapt to the growing demand for personalized medicine and innovative therapeutic solutions.</p>

Get more detailed insights about Biobanking Market Research Report-Forecast to 2035

Regional Insights

North America : Market Leader in Biobanking

North America is poised to maintain its leadership in the biobanking market, holding a significant 40.0% share as of 2024. The region's growth is driven by increasing investments in healthcare research, advancements in biobanking technologies, and a robust regulatory framework that supports biobanking initiatives. The demand for personalized medicine and regenerative therapies further fuels this growth, as institutions seek to enhance their biobanking capabilities to meet evolving healthcare needs. The competitive landscape in North America is characterized by the presence of key players such as Thermo Fisher Scientific, Illumina, and BioLife Sciences. These companies are at the forefront of innovation, offering advanced biobanking solutions that cater to diverse research requirements. The U.S. and Canada are leading countries in this sector, with numerous biobanks established to support both academic and commercial research endeavors. The region's strong infrastructure and funding opportunities continue to attract investments, solidifying its position as a biobanking powerhouse.

Europe : Emerging Biobanking Hub

Europe is emerging as a significant player in the biobanking market, with a market share of 25.0% as of 2024. The region benefits from strong governmental support and regulatory frameworks that promote biobanking initiatives. Increasing collaborations between academic institutions and biobanks, along with rising public awareness about the importance of biobanking in research, are key drivers of growth. The focus on personalized medicine and genetic research is also propelling demand for biobanking services across Europe. Leading countries in Europe include Germany, the UK, and France. Germany Biobanking market is a strong plater with host of cutting-edge biobanking technologies, including fully automated robotic storage systems, AI-driven sample management, and integrated virtual platforms that enable seamless cross-institutional research. The Italy Market is witnessing exceptional progress in this market Italy boasts one of the most sophisticated networks under the BBMRI-ERIC (Biobanking and BioMolecular Resources Research Infrastructure) umbrella, with over 90 biobanks collaborating to standardize sample quality and ethical protocols. The Italy market is heavily concentrated on disease-specific biobanks, particularly for rare diseases, cardiovascular health, and various cancers. Italy’s progress in this market is promoting Europe as a critical region in this market which host numerous biobanks and research facilities.

 Key players such as Qiagen and Merck KGaA are instrumental in driving innovation and expanding service offerings. The competitive landscape is characterized by a mix of established companies and emerging startups, fostering a dynamic environment for growth. As Europe continues to enhance its biobanking capabilities, it is set to play a crucial role in global health research.

Asia-Pacific : Growing Biobanking Potential

The Asia-Pacific region is witnessing a gradual rise in the biobanking market size, currently holding an 8.0% share as of 2024. This growth is primarily driven by increasing investments in healthcare infrastructure, rising awareness of biobanking's role in research, and government initiatives aimed at enhancing biobanking capabilities. The demand for biobanks is also fueled by the growing prevalence of chronic diseases and the need for personalized medicine solutions in the region. 

Countries like Japan, China, and Australia are leading the charge in biobanking initiatives, with significant investments from both public and private sectors. Key players such as ReproCELL and STEMCELL Technologies are expanding their presence, contributing to the competitive landscape. As the region continues to develop its biobanking infrastructure, it is expected to see substantial growth in the coming years, positioning itself as a vital player in The Biobanking.

Middle East and Africa : Emerging Market Opportunities

The Middle East and Africa region is gradually emerging in the biobanking market, currently holding a modest 2.39% share as of 2024. The growth in this region is driven by increasing healthcare investments, rising awareness of biobanking's significance in research, and the establishment of regulatory frameworks to support biobanking initiatives. The demand for biobanked samples is expected to rise as healthcare systems evolve and focus on personalized medicine and research advancements. Countries like South Africa and the UAE are leading the way in developing biobanking capabilities, with several initiatives aimed at enhancing research infrastructure. The competitive landscape is characterized by a mix of local and international players, with a focus on building partnerships to improve biobanking practices. As the region continues to develop, opportunities for growth in biobanking are expected to expand significantly, driven by both public and private sector investments.

Key Players and Competitive Insights

The Biobanking Market is currently characterized by a dynamic competitive landscape, driven by advancements in technology, increasing demand for personalized medicine, and a growing emphasis on research and development. Key players such as Thermo Fisher Scientific (US), Qiagen (DE), and Illumina (US) are strategically positioned to leverage these trends. Thermo Fisher Scientific (US) focuses on innovation through its extensive portfolio of biobanking solutions, while Qiagen (DE) emphasizes partnerships to enhance its product offerings. Illumina (US) is heavily invested in digital transformation, aiming to streamline operations and improve data management, which collectively shapes a competitive environment that is increasingly reliant on technological advancements and strategic collaborations.The market structure appears moderately fragmented, with a mix of established players and emerging companies. Key business tactics such as localizing manufacturing and optimizing supply chains are prevalent among major players. This approach not only enhances operational efficiency but also allows companies to respond swiftly to regional demands. The collective influence of these key players fosters a competitive atmosphere where innovation and strategic positioning are paramount.


In November Thermo Fisher Scientific (US) announced the launch of a new biobanking platform designed to enhance sample management and data integration. This strategic move is significant as it positions the company to meet the increasing demand for efficient biobanking solutions, particularly in the context of personalized medicine. By streamlining sample tracking and data analysis, Thermo Fisher aims to solidify its market leadership and cater to the evolving needs of researchers and healthcare providers.


In October Qiagen (DE) expanded its collaboration with a leading academic institution to develop advanced biobanking protocols. This partnership is indicative of Qiagen's strategy to enhance its research capabilities and broaden its product offerings. By aligning with academic leaders, Qiagen not only strengthens its innovation pipeline but also gains access to cutting-edge research that could inform future product development.


In September Illumina (US) unveiled a new AI-driven analytics tool aimed at improving biobanking data interpretation. This tool is expected to revolutionize how researchers analyze genetic data, thereby enhancing the overall utility of biobanked samples. The integration of AI into biobanking operations reflects a broader trend towards digitalization, positioning Illumina as a frontrunner in leveraging technology to enhance research outcomes.


As of December current competitive trends in the Biobanking Market are heavily influenced by digitalization, sustainability, and AI integration. Strategic alliances are increasingly shaping the landscape, allowing companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift underscores the importance of adaptability and forward-thinking strategies in maintaining a competitive edge in the Biobanking Market.

Key Companies in the Biobanking Market include

Industry Developments

In an effort to increase diversity and advance personalized medicine initiatives, the U.S. National Institutes of Health (NIH) extended the All of Us Research Program in June 2025 to include the biospecimens of 500,000 more individuals.

In order to strengthen domestic sample integrity and supply, Thermo Fisher Scientific stated in May 2025 that it will invest $2 billion to modernize cold-chain and analytical facilities inside its biobanking division in North America.

With £45 million in financing, a partnership led by Genomics England and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) launched Project Genome of Europe in March 2025 with the goal of accelerating pan-EU research collaborations and harmonizing cross-national biobanking standards.

In order to strengthen Asia-Pacific research capacity, AIG Hospital in southern India launched its first regional biobank in November 2024 with the goal of collecting and storing over 100,000 tissue and blood samples over the next ten years.

Initial results showing effective federated learning deployment across biobanks for multiple sclerosis research were released in October 2024 by the Clinnova effort, a cooperation between France, Germany, Switzerland, and Luxembourg, emphasizing privacy protection and interoperability.

The European biobanking network, BBMRI-ERIC, announced in April 2024 that the number of participating institutions had increased by 12%, indicating improved standardization and sample-sharing capabilities. Additionally, around 25% of biobanks in North America explored blockchain initiatives in early 2024 to safeguard data access and sample tracking processes.

Future Outlook

Biobanking Market Future Outlook

<p>The Biobanking Market is projected to grow at a 4.12% CAGR from 2025 to 2035, driven by advancements in personalized medicine, increased research funding, and technological innovations.</p>

New opportunities lie in:

  • <p>Expansion of biobanking services into emerging markets Development of automated sample processing technologies Partnerships with pharmaceutical companies for drug discovery initiatives</p>

<p>By 2035, the Biobanking Market is expected to be robust, driven by strategic innovations and global collaborations.</p>

Market Segmentation

Biobanking Market End User Outlook

  • Academic Institutions
  • Biotechnology Companies
  • Pharmaceutical Companies
  • Hospitals

Biobanking Market Application Outlook

  • Research
  • Clinical Trials
  • Regenerative Medicine
  • Pharmaceutical Development

Biobanking Market Sample Type Outlook

  • Blood
  • Tissue
  • Cells
  • DNA
  • RNA

Biobanking Market Storage Type Outlook

  • Cryopreservation
  • Ambient Storage
  • Liquid Nitrogen Storage
  • Freezer Storage

Report Scope

MARKET SIZE 2024 75.39(USD Billion)
MARKET SIZE 2025 78.5(USD Billion)
MARKET SIZE 2035 117.55(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 4.12% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled Thermo Fisher Scientific (US), Qiagen (DE), Illumina (US), Merck KGaA (DE), STEMCELL Technologies (CA), BioLife Sciences (US), Tecan Group (CH), Biosample Solutions (US), ReproCELL (JP)
Segments Covered Application, Sample Type, Storage Type, End User
Key Market Opportunities Integration of advanced genomic technologies enhances personalized medicine applications in the Biobanking Market.
Key Market Dynamics Rising demand for personalized medicine drives innovation and competition in the biobanking sector.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the projected growth of the Biobanking market?

The Biobanking market is the expected increase in total market value of 117.55 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion.

What is the size of the Biobanking market?

Biobanking market size was valued at approximately 75.39 billion USD in 2024. This figure will reach 117.55 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035.

What is the CAGR of the Biobanking market?

Biobanking market is expected to grow at a CAGR of 4.12% between 2025 and 2035.

How much will the Biobanking market be worth by 2035?

Biobanking market is expected to be worth of 117.55 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035.

How will the Biobanking market perform over the next 10 years?

Over the next 10 years the Biobanking market is expected to shift from usd billion 75.39 to 117.55 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035.

What was the market size of the Biobanking Market in 2024?

The Biobanking Market was valued at 5.14 billion USD in 2024.

What will the market size be for the European region in 2035?

The market size for Europe is projected to reach 2.1 billion USD by 2035.

What was the market size for blood products in 2024?

The market size for blood products in 2024 was 1.5 billion USD.

Who are the key players in the Biobanking Market?

Key players include Becton Dickinson, Biolife Solutions, and Thermo Fisher Scientific among others.

What is the anticipated market size for microbiome samples by 2035?

The anticipated market size for microbiome samples in 2035 is expected to be 0.2 billion USD.

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. | 1.1 EXECUTIVE SUMMARY
    2. | 1.1.1 Market Overview
    3. | 1.1.2 Key Findings
    4. | 1.1.3 Market Segmentation
    5. | 1.1.4 Competitive Landscape
    6. | 1.1.5 Challenges and Opportunities
    7. | 1.1.6 Future Outlook
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. | 2.1 MARKET INTRODUCTION
    2. | 2.1.1 Definition
    3. | 2.1.2 Scope of the study
    4. |-- 2.1.2.1 Research Objective
    5. |-- 2.1.2.2 Assumption
    6. |-- 2.1.2.3 Limitations
    7. | 2.2 RESEARCH METHODOLOGY
    8. | 2.2.1 Overview
    9. | 2.2.2 Data Mining
    10. | 2.2.3 Secondary Research
    11. | 2.2.4 Primary Research
    12. |-- 2.2.4.1 Primary Interviews and Information Gathering Process
    13. |-- 2.2.4.2 Breakdown of Primary Respondents
    14. | 2.2.5 Forecasting Model
    15. | 2.2.6 Market Size Estimation
    16. |-- 2.2.6.1 Bottom-Up Approach
    17. |-- 2.2.6.2 Top-Down Approach
    18. | 2.2.7 Data Triangulation
    19. | 2.2.8 Validation
  3. SECTION III: QUALITATIVE ANALYSIS
    1. | 3.1 MARKET DYNAMICS
    2. | 3.1.1 Overview
    3. | 3.1.2 Drivers
    4. | 3.1.3 Restraints
    5. | 3.1.4 Opportunities
    6. | 3.2 MARKET FACTOR ANALYSIS
    7. | 3.2.1 Value chain Analysis
    8. | 3.2.2 Porter's Five Forces Analysis
    9. |-- 3.2.2.1 Bargaining Power of Suppliers
    10. |-- 3.2.2.2 Bargaining Power of Buyers
    11. |-- 3.2.2.3 Threat of New Entrants
    12. |-- 3.2.2.4 Threat of Substitutes
    13. |-- 3.2.2.5 Intensity of Rivalry
    14. | 3.2.3 COVID-19 Impact Analysis
    15. |-- 3.2.3.1 Market Impact Analysis
    16. |-- 3.2.3.2 Regional Impact
    17. |-- 3.2.3.3 Opportunity and Threat Analysis
  4. SECTION IV: QUANTITATIVE ANALYSIS
    1. | 4.1 Healthcare, BY Application (USD Billion)
    2. | 4.1.1 Research
    3. | 4.1.2 Clinical Trials
    4. | 4.1.3 Regenerative Medicine
    5. | 4.1.4 Pharmaceutical Development
    6. | 4.2 Healthcare, BY Sample Type (USD Billion)
    7. | 4.2.1 Blood
    8. | 4.2.2 Tissue
    9. | 4.2.3 Cells
    10. | 4.2.4 DNA
    11. | 4.2.5 RNA
    12. | 4.3 Healthcare, BY Storage Type (USD Billion)
    13. | 4.3.1 Cryopreservation
    14. | 4.3.2 Ambient Storage
    15. | 4.3.3 Liquid Nitrogen Storage
    16. | 4.3.4 Freezer Storage
    17. | 4.4 Healthcare, BY End User (USD Billion)
    18. | 4.4.1 Academic Institutions
    19. | 4.4.2 Biotechnology Companies
    20. | 4.4.3 Pharmaceutical Companies
    21. | 4.4.4 Hospitals
    22. | 4.5 Healthcare, BY Region (USD Billion)
    23. | 4.5.1 North America
    24. |-- 4.5.1.1 US
    25. |-- 4.5.1.2 Canada
    26. | 4.5.2 Europe
    27. |-- 4.5.2.1 Germany
    28. |-- 4.5.2.2 UK
    29. |-- 4.5.2.3 France
    30. |-- 4.5.2.4 Russia
    31. |-- 4.5.2.5 Italy
    32. |-- 4.5.2.6 Spain
    33. |-- 4.5.2.7 Rest of Europe
    34. | 4.5.3 APAC
    35. |-- 4.5.3.1 China
    36. |-- 4.5.3.2 India
    37. |-- 4.5.3.3 Japan
    38. |-- 4.5.3.4 South Korea
    39. |-- 4.5.3.5 Malaysia
    40. |-- 4.5.3.6 Thailand
    41. |-- 4.5.3.7 Indonesia
    42. |-- 4.5.3.8 Rest of APAC
    43. | 4.5.4 South America
    44. |-- 4.5.4.1 Brazil
    45. |-- 4.5.4.2 Mexico
    46. |-- 4.5.4.3 Argentina
    47. |-- 4.5.4.4 Rest of South America
    48. | 4.5.5 MEA
    49. |-- 4.5.5.1 GCC Countries
    50. |-- 4.5.5.2 South Africa
    51. |-- 4.5.5.3 Rest of MEA
  5. SECTION V: COMPETITIVE ANALYSIS
    1. | 5.1 Competitive Landscape
    2. | 5.1.1 Overview
    3. | 5.1.2 Competitive Analysis
    4. | 5.1.3 Market share Analysis
    5. | 5.1.4 Major Growth Strategy in the Healthcare
    6. | 5.1.5 Competitive Benchmarking
    7. | 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
    8. | 5.1.7 Key developments and growth strategies
    9. |-- 5.1.7.1 New Product Launch/Service Deployment
    10. |-- 5.1.7.2 Merger & Acquisitions
    11. |-- 5.1.7.3 Joint Ventures
    12. | 5.1.8 Major Players Financial Matrix
    13. |-- 5.1.8.1 Sales and Operating Income
    14. |-- 5.1.8.2 Major Players R&D Expenditure. 2023
    15. | 5.2 Company Profiles
    16. | 5.2.1 Thermo Fisher Scientific (US)
    17. |-- 5.2.1.1 Financial Overview
    18. |-- 5.2.1.2 Products Offered
    19. |-- 5.2.1.3 Key Developments
    20. |-- 5.2.1.4 SWOT Analysis
    21. |-- 5.2.1.5 Key Strategies
    22. | 5.2.2 Qiagen (DE)
    23. |-- 5.2.2.1 Financial Overview
    24. |-- 5.2.2.2 Products Offered
    25. |-- 5.2.2.3 Key Developments
    26. |-- 5.2.2.4 SWOT Analysis
    27. |-- 5.2.2.5 Key Strategies
    28. | 5.2.3 Illumina (US)
    29. |-- 5.2.3.1 Financial Overview
    30. |-- 5.2.3.2 Products Offered
    31. |-- 5.2.3.3 Key Developments
    32. |-- 5.2.3.4 SWOT Analysis
    33. |-- 5.2.3.5 Key Strategies
    34. | 5.2.4 Merck KGaA (DE)
    35. |-- 5.2.4.1 Financial Overview
    36. |-- 5.2.4.2 Products Offered
    37. |-- 5.2.4.3 Key Developments
    38. |-- 5.2.4.4 SWOT Analysis
    39. |-- 5.2.4.5 Key Strategies
    40. | 5.2.5 STEMCELL Technologies (CA)
    41. |-- 5.2.5.1 Financial Overview
    42. |-- 5.2.5.2 Products Offered
    43. |-- 5.2.5.3 Key Developments
    44. |-- 5.2.5.4 SWOT Analysis
    45. |-- 5.2.5.5 Key Strategies
    46. | 5.2.6 BioLife Sciences (US)
    47. |-- 5.2.6.1 Financial Overview
    48. |-- 5.2.6.2 Products Offered
    49. |-- 5.2.6.3 Key Developments
    50. |-- 5.2.6.4 SWOT Analysis
    51. |-- 5.2.6.5 Key Strategies
    52. | 5.2.7 Tecan Group (CH)
    53. |-- 5.2.7.1 Financial Overview
    54. |-- 5.2.7.2 Products Offered
    55. |-- 5.2.7.3 Key Developments
    56. |-- 5.2.7.4 SWOT Analysis
    57. |-- 5.2.7.5 Key Strategies
    58. | 5.2.8 Biosample Solutions (US)
    59. |-- 5.2.8.1 Financial Overview
    60. |-- 5.2.8.2 Products Offered
    61. |-- 5.2.8.3 Key Developments
    62. |-- 5.2.8.4 SWOT Analysis
    63. |-- 5.2.8.5 Key Strategies
    64. | 5.2.9 ReproCELL (JP)
    65. |-- 5.2.9.1 Financial Overview
    66. |-- 5.2.9.2 Products Offered
    67. |-- 5.2.9.3 Key Developments
    68. |-- 5.2.9.4 SWOT Analysis
    69. |-- 5.2.9.5 Key Strategies
    70. | 5.3 Appendix
    71. | 5.3.1 References
    72. | 5.3.2 Related Reports

Healthcare Market Segmentation

Healthcare By Application (USD Billion, 2025-2035)

  • Research
  • Clinical Trials
  • Regenerative Medicine
  • Pharmaceutical Development

Healthcare By Sample Type (USD Billion, 2025-2035)

  • Blood
  • Tissue
  • Cells
  • DNA
  • RNA

Healthcare By Storage Type (USD Billion, 2025-2035)

  • Cryopreservation
  • Ambient Storage
  • Liquid Nitrogen Storage
  • Freezer Storage

Healthcare By End User (USD Billion, 2025-2035)

  • Academic Institutions
  • Biotechnology Companies
  • Pharmaceutical Companies
  • Hospitals
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

Customer Stories
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓